Most Read This Week
- ESMO 2024: Risk for Recurrence High for HR-Positive/HER2-Negative High-Risk Node-Negative Early Breast Cancer
- Neoadjuvant Nivolumab vs Nivolumab Plus Ipilimumab for Early-Stage TNBC
- PSA Screening Combined With MRI-Targeted Biopsy for Detecting Prostate Cancer
- Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer
- Datopotamab–Deruxtecan Plus Durvalumab for Early-Stage Breast Cancer
Recently Updated
- Hematologic Cancer Develops in Some Patients Receiving Eli-Cel
- Aerobic Physical Activity Reduces Depression in Patients With Cancer
- Time to Testosterone Recovery Varies With ADT Duration
- Increasing Amount of Breast Cancer-Specific Death Due to Stage 1, 2 Disease
- Availability, Timeliness of Availability of New Cancer Drugs Vary